It turns out that ARNA is putting out a fair amount of material - in 8k's. And regarding the above issue it is in fact true that the BLOOM-DM trial put them over the ARNA described limits that the FDA gave to them for valvulopathy. See the below quotes from the linked 8k :
MITT-LOCF is the analysis used everywhere else in ARNA's submissions and was not objected to in the last AC - but as you can see from the italicized text ARNA now fails the FDA criteria for ruling out valvulopathy.
On a wider note - it appears that ARNA may have gotten pretty good at hiding the negative data in text most people won't understand in documents most people don't read - while still protecting themselves from lawsuits.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.